Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8328893 | 0.77 | TSHR (0.36) | TSHR | |
| SCHEMBL634591 | 0.77 | TSHR (0.36) | TSHR | |
| SCHEMBL26630548 | 0.75 | — | — | |
| SCHEMBL8509214 | 0.74 | TSHR (0.33) | TSHR | |
| SCHEMBL4819967 | 0.74 | TSHR (0.30) | TSHR | |
| SCHEMBL26471041 | 0.72 | — | — | |
| SCHEMBL21697444 | 0.71 | TSHR (0.39) | TSHR | |
| SCHEMBL20386983 | 0.71 | TSHR (0.39) | TSHR | |
| SCHEMBL20214657 | 0.71 | TSHR (0.31) | TSHR | |
| SCHEMBL285592 | 0.69 | TSHR (0.30) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210775-A1 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS, INC. | 2017-07-27 | — | — | US | claimed |
| US-9637515-B2 | Guggulphospholipid methods and compositions | JINA PHARMACEUTICALS, INC. (US) | 2017-05-02 | — | — | US | claimed |
| EP-2088865-B1 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS INC (US) | 2015-10-21 | — | — | EP | claimed |
| US-20100151002-A1 | Guggulphospholipid Methods and Compositions | JINA PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | claimed |
| EP-1223173-B1 | Novel 2'-O-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof | ISIS PHARMACEUTICALS INC (US) | 2005-07-13 | — | — | EP | claimed |
| EP-0651759-B1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS INC (US) | 2003-12-10 | — | — | EP | claimed |
| EP-1223173-A2 | Novel 2'-O-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof | ISIS PHARMACEUTICALS, INC. (US) | 2002-07-17 | — | — | EP | claimed |
| US-12637672-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2026-05-26 | — | — | US | disclosed |
| US-20260076989-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD (SG) | 2026-03-19 | — | — | US | disclosed |
| US-12403156-B2 | Oligonucleotides, compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2025-09-02 | — | — | US | disclosed |
| US-20240117347-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-04-11 | — | — | US | disclosed |
| US-20240025928-A1 | CARDIOPROTECTIVE LIPIDS AND METHODS OF USE | SIGNPATH PHARMA INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025928-A1 | CARDIOPROTECTIVE LIPIDS AND METHODS OF USE | SIGNPATH PHARMA INC (US) | 2024-01-25 | — | — | US | disclosed |
| WO-1992001476-A1 | NOVEL DRUG DELIVERY SYSTEMS FOR PROTEINS AND PEPTIDES USING ALBUMIN AS A CARRIER MOLECULE | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1992-02-06 | — | — | WO | disclosed |
| EP-0424819-A1 | Reversible modification of biological compounds for detection, separation and purification thereof | MILLIPORE CORPORATION (US) | 1991-05-02 | — | — | EP | disclosed |
| WO-1990015040-A1 | CHEMILUMINESCENT DOUBLE-TRIGGERED 1,2-DIOXETANES | CHIRON CORPORATION (US) | 1990-12-13 | — | — | WO | disclosed |
| EP-0401001-A2 | Chemiluminescent doubletriggered 1,2-dioxetanes | CHIRON CORPORATION (US) | 1990-12-05 | — | — | EP | disclosed |
| EP-0354904-A1 | INOSITOL PHOSPHATE ANALOGUES | 3i RESEARCH EXPLOITATION LIMITED (GB) | 1990-02-21 | — | — | EP | disclosed |
| WO-1989009780-A1 | SITE-SPECIFIC TRITIUM-LABELED OLIGODEOXYNUCLEOTIDES | CHEMICAL INDUSTRY INSTITUTE OF TOXICOLOGY (US) | 1989-10-19 | — | — | WO | disclosed |
| WO-1988007047-A1 | INOSITOL PHOSPHATE ANALOGUES | RESEARCH CORPORATION LIMITED (GB) | 1988-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076989-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | NSUN2, TLR9, MSR1 | TSHR 1155/4885 |
| US-20240025928-A1 | CARDIOPROTECTIVE LIPIDS AND METHODS OF USE | CPT1B, FABP3, NR1H2 | TSHR 1085/4885 |
| US-20100151002-A1 | Guggulphospholipid Methods and Compositions | SGMS2, SGMS1, PLA2G5 | TSHR 3804/4885 |
| US-20240117347-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RBM17, HNRNPA2B1, HNRNPA1 | TSHR 3181/4885 |
| US-12403156-B2 | Oligonucleotides, compositions and methods thereof | TLR9, RNGTT, NT5C3B | TSHR 2966/4885 |
| US-12637672-B2 | Oligonucleotide compositions and methods thereof | UPF1, SMN1; SMN2, RNGTT | TSHR 1552/4885 |
| US-20170210775-A1 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | SGMS1, SGMS2, GGPS1 | TSHR 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.